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Smoking is related to 30% of cancer deaths. It is a risk factor 
for respiratory tract, esophagus, stomach, pancreas, uterine 
cervix, kidney and bladder carcinomas. Nicotine induces 
tolerance and addiction by acting on the central dopaminergic 
pathways, thus leading to pleasure and reward sensations 
within the limbic system. It stimulates the central nervous 
system (CNS), enhances alertness and reduces the appetite. 
A 50% reduction of nicotine consumption may trigger 
withdrawal symptoms in addicted individuals: anxiety, anger, 
sleep disorders, hunger, cognitive dysfunction and cigarette 
craving. Medical advice is the cornerstone of smoking 
cessation. Pharmacotherapy of nicotine addiction comprises 
first-line (bupropion and nicotine replacement therapy) and 
second-line (clonidine and nortriptyline) drugs. Bupropion is 
a non-tricyclic antidepressant that inhibits dopamine uptake, 
whose contraindications are: epilepsy, eating disorders, 
uncontrolled hypertension, recent alcohol abstinence and 
current therapy with MAO inhibitors. Nicotine replacement 
therapy can be done with patches or gums. Counseling 
groups and behavioral interventions are efficacious. The 
effects of acupuncture on smoking cessation are not fully 
elucidated. Prompt smoking cessation or gradual reduction 
strategies have similar success rates.
Key words: smoking, nicotine, tobacco use disorder,  
tobacco use cessation, bupropion.
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INTRODUCTION
Tobacco is produced by two plant species - Nico-
tiana tabacum and Nicotiana rustica, which come from 
the Peruvian and equatorial Andes. These plants were 
found out approximately 18,000 years ago, when Asiatic 
populations migrated to America1.
When Christopher Columbus arrived in the New 
World, the cultivation and use of tobacco had already 
been disseminated among Indians over the continent. It 
had several applications, including religious rituals and as 
insecticide in agriculture. Tobacco was smoked in pipes, 
inhaled, chewed, eaten, and drunk as tea. Important 
medicinal plant, it was used for intestinal wash-ups, skin 
smear to kill louses, instilled as eye-wash and used in 
ointments, analgesic and antiseptic formulations1.
Aware of smoking habits and the tobacco medicinal 
properties, explorers decided to take the plant seeds to 
Europe. In Portugal and in Spain, tobacco was cultivated 
in royal palace gardens, while nobles used it to fight can-
cer. Rapidly, tobacco became much valuable in Europe, 
while English pirates invaded and plundered Spanish ships 
coming from America, till the British government decided 
to cultivate the plant in several colonies1.
In 1850, the first manufactured cigarettes were sold 
in England, whose consumption became popular during 
the First World War. Smoking habits summit took place in 
the 50 and 60’s, declining in certain countries from 1970 
and on1. Today, there are more than a billion tobacco us-
ers around the world, among which 90% started smoking 
in the adolescence2.
From 1920’s, the increase of lung cancer incidence 
was observed, which was confirmed in several studies 
thirty years later. In 1971, a formal report was published 
in the United States confirming that “smoking negatively 
affects human health and contributes for the onset of 
severe diseases”1.
Currently, the World Health Organization accounts 
for more than four millions fatal victims caused by ciga-
rette each year2. It is known that smoking is related to at 
least 30% of cancer deaths. It is a risk factor for the onset 
of lung, mouth, pharynx, larynx, esophagus, stomach, 
pancreas, uterine cervix, kidney and bladder carcinomas3. 
Moreover, morbidity by cardiovascular and cerebrovascular 
diseases, chronic obstructive pulmonary diseases (COPD) 
and peptic diseases, as well as other affections, is higher 
among smokers1.
In 1988, a new North-American report concluded 
that nicotine found in cigarettes and in other tobacco 
products is a drug that causes dependence. It is estimated 
that 24% of the adult population in several countries, Brazil 
included, are nicotine dependent4.
Frequently, otorhinolaryngologists receive smokers 
with inflammatory or tumoral diseases of the upper air-
ways. It is fundamental to diagnose and treat the chemical 
dependence in these patients, promoting smoking cessa-
tion in order to prevent or cure these affections.
The authors present a pharmacology outlook, ad-
dressing actions and nicotine dependence, as well as 
treatment modalities available for smoking cessation which 
may be prescribed by otorhinolaryngologists.
Literature Review
Indexed studies were reviewed through Lilacs and 
Medline databases under the keywords in Portuguese, 
such as “tabagismo”, “nicotina”, “transtorno por uso do 
tabaco”, “abandono do uso do tabaco”, “bupropiona” or 
its related links in English: “smoking”, “nicotine”, “tobacco 
use disorder”, “tobacco use cessation”, “bupropion”.
Nicotine Pharmacology
Cigarette smoke consists of volatile chemical sub-
stances (92%) and particulate material (8%) resultant of 
tobacco combustion5. Nicotine, a tertiary volatile amine, 
is the most important active tobacco component4,6. When 
tobacco coal’s temperature reaches 800°C, racemic shapes 
of nicotine emerge, which form four nitrosamines with 
cancer potential7. However, nearly 35% of nicotine is de-
stroyed during cigarette combustion; more than 35% is lost 
in non-inhaled smoke and 8% is not smoked6. Therefore, 
each cigarette contains 7-9 mg of nicotine, of which a 
little more than 1 mg is absorbed by the smoker4. Cured 
tobacco’s nicotine for pipes and cigars is alkaline and it 
is more easily absorbed through the mouth. On the other 
hand, cigarette’s nicotine is acid, therefore it is practically 
not absorbed by the mouth mucosa, and has to be inhaled 
to be absorbed by the lungs1,7.
Nicotine is rapidly absorbed by the lung alveolus 
and reaches the brain within 10 seconds. Its half-life is 
of approximately 2 hours, and metabolization is mostly 
hepatic, through P450 cytochrome. The main enzyme in-
volved is CYP2A6. Molecular biology studies demonstrate 
that capacity in metabolizing nicotine varies according 
to each individual7. CYP2A6*2 and CYP2A6*3-allele in-
dividuals are less prone to be smokers, and if they do, 
they tend to consume less tobacco than CYP2A6*1-allele 
individuals8.
Vasconcelos et al. (2005)9 analyzed the genetic 
profile of CYP2A6 in a sample of an adult Brazilian 
population, composed by 147 Caucasian individuals, 142 
Mulattos and 123 Blacks, among which 205 were smokers 
or ex-smokers, and 207 were non-smokers. The alleles 
mostly found in this sample were: CYP2A6*1B (29.9%), 
CYP2A6*2 (1.7%), CYP2A6*4 (0.5%) and CYP2A6*9 (5.7%). 
Contrary to expectations, frequency of CYP2A6*1B-allel 
individuals among non-smokers was higher. Distribution 
of CYP2A6*1B alleles also presented racial differences, 
with decreasing frequency among Caucasians, Mulattos 
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and Blacks. Presence of this allele was associated with a 
higher probability of nicotine dependency among Cauca-
sians (a 14-fold higher risk) and Mulatto (a 3-fold higher 
risk), but not among Blacks.
The most important nicotine metabolite is cotinine, 
which can be detected in urine, saliva and blood7. Only 
5% of nicotine is excreted without alterations by the 
kidneys4.
Nicotine actions
The systemic actions of nicotine are mediated by 
nicotinic receptors found in the central nervous system 
(CNS), peripheral autonomic nodes, supra-renal glands, 
sensitive nerves and the skeletal striated muscle4.
Nicotine’s main acute effects over the cardiovascular 
system are10: peripheral vasoconstriction, increase of the 
blood pressure and heart rate. Nicotine also interferes in 
the endocrine system, yielding the release of antidiuretic 
hormone and water retention. In the gastrointestinal sys-
tem, nicotine acts parasympathetically, stimulating tonus 
increase and intestinal motor activity10.
In nervous endings, nicotine stimulates release of 
the following neurotransmitters: acetylcholine, dopamine 
(DA), glutamate, serotonin and gamma aminobutyric acid 
(GABA)11.
Nicotine is CNS stimulant, leading to increased alert-
ness and to reduced appetite. After a draft, the sensation 
may be compared to that described by amphetamine, 
heroine, cocaine and crack users4. The main sensations 
may include dizziness, nauseas and vomiting10.
Rose et al. (2003)11 studied nicotine’s acute effects 
over the brain blood flow in adults through tomography 
by positrons emission (PET). Nicotine interferes in the re-
ticular formation blood flow, including areas of the pons, 
mesencephalus and thalamus, and plays a role in aware-
ness and awakening mechanisms. Low doses of nicotine 
have a central stimulating effect, while higher doses have 
a depressing effect. Nicotine also leads to dose-dependent 
increase of blood flow in the left hemisphere amygdala, 
which may explain the anxiolytic effect of smoking.
Experimental studies show that nicotine acts as en-
zymatic inductor in the liver. This way it reduces half-life 
of several medicines such as: local anesthetics, morphine, 
codeine, teophyline, heparin, warfarin, amitriptyline, 
imipramine, propranolol, chlorpromazine, diazepam, 
chlordiazepoxide and indometacin. Thus, smokers may 
require larger doses of these medicines to have the ex-
pected therapeutic effects10.
Ingestion of nicotine-based insecticides may cause 
acute intoxication, with the following symptoms: salivation, 
vomiting, muscle weakness, prostration, cold sudoresis, 
mental confusion and hypotension. In severe cases (inges-
tion of over 60 mg of nicotine), chronic convulsions and 
respiratory failure may occur10.
Nicotine Chemical Dependency
Nicotine induces tolerance (need of progressively 
higher doses to obtain the same effect) and dependence 
(desire of consumption) as it acts in the dopaminergic 
pathways of the mesolimbic system, reducing the tha-
lamus activity4. Similarly to other psychoactive drugs, it 
releases dopamine in the nucleus accumbens, located in 
the mesencephalus, stimulating a pleasant and “rewarding” 
sensation8,12. After the discomfort caused by the first drafts 
of tobacco (sickness, dizziness, nausea), the smoker expe-
rience a pleasant sensation with the use of nicotine7.
According to Marques et al. (2001)4, a 50% decrease 
in nicotine consumption is enough to trigger withdrawal 
symptoms in dependent individuals. Nicotine abstinence 
syndrome is mediated by noradrenalin and starts 8 hours 
after the last cigarette, reaching a peak on the third day. 
Main symptoms include: anxiety, irritability, sleep disorders 
(insomnia and daytime sleepiness), appetite increase, cog-
nitive disorders (decrease of concentration and attention) 
and craving. That is why nicotine-dependent individuals 
present abstinence relief when they smoke their first 
morning cigarette.
Irritability during nicotine withdrawal is a common 
smokers’ complaint4. Our experience includes a 34-year-
old patient that used to smoke about 12 cigarettes per 
day and had quit smoking for two months. The patient 
says she had physically improved during withdrawal, but 
started smoking again due to her husband’s insistence: 
“He could no longer stand my bad mood”.
Unwanted weight gain is one of the symptoms that 
mostly upset patients under nicotine abstinence. Mostly, 
weight gain gets around 4 to 6 Kg13, and in some people 
it may reach 10% of body weight4.
Women and smokers that smoke over 25 cigarettes 
per day tend to gain weight after smoking cessation, prob-
ably due to food ingestion and metabolic adjustments4.
Epidemiologic studies show that more than 70% of 
smokers want to quit smoking8. However, less than 10% 
reach their goal by their own, as discomfort caused by 
nicotine abstinence and craving leads most ex-smokers to 
relapse8,13. Relapses usually occur between two days and 
three months of withdrawal13.
Cox et al. (2003)3 alert that 58% of cancer patients 
continue smoking after diagnosis, usually due to behavioral 
habit, anxiety or stress.
Treatment of Nicotine Dependency
Medical support may enhance the success rate in 
smoking cessation13.
Patient and Family Counseling 
Talking with the patient is the first step for smok-
ing cessation. It is important to evaluate if the patient is 
823
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 71 (6) PART 1 NOVEMBER/DECEMBER 2005
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
nicotine-dependent or not, the quantity smoked, desire to 
quit, presence of associated diseases and feasible treat-
ment modalities4,6.
There are many ways to assess nicotine depend-
ency: through the International Classification of Diseases 
(ICD-10), Diagnosis and Statistics Manual of the Ameri-
can Psychiatric Association (DSM-IV), and others4. The 
Fagerström Scale for nicotine tolerance and dependency 
assessment (Table 1) has English and Swedish originals 
and has been adapted to several languages. It includes 
six questions. Total score ranges from zero to 11, where 
low nicotine dependency (mild) is detected when total is 
below three. A score higher or equal to seven indicates 
high nicotine dependency (severe)6. Patient should be 
encouraged to quit smoking at each medical consultation. 
Other smokers in the family must also be counseled not 
to smoke3. According to Jain (2003)13, gradual reduction 
or quit attempts to smoking cessation show the same 
probability of success.
Pharmacotherapy
Pharmacotherapy is indicated for nicotine depend-
ents and is divided into: first-line therapy (bupropion and 
nicotine-replacement therapy) and second-line therapy 
(clonidine and nortriptyline).
First-line Therapy
Bupropion
Bupropion is a non-tricyclic antidepressive that 
inhibits pre-synaptic dopaminergic and noradrenalin 
mechanisms8,14,15. Its action in the central dopaminergic 
pathways is believed to be the same mechanism respon-
sible for craving reduction in patients under nicotine 
abstinency14.
In the United States, bupropion is indicated for 
addicts smoking 15 or more cigarettes/day or presenting 
depressive symptoms4.
Bupropion therapy should start 7 to 10 days before 
patient stops smoking, since this interval is necessary for 
the balance of pharmacotherapeutic levels2,8. The rec-
ommended dosage is 150mg/day up to the third day of 
treatment, increasing to 300mg/day at the fourth day, and 
maintaining this dosage from 7 up to 12 weeks4.
Clinical studies with bupropion have satisfactory 
results, presenting twice the period of abstinence when 
compared with placebo, plus reduced weight gain4.
Bupropion’s adverse effects occur in 6-8% of 
patients16. The most common symptoms are: insomnia, 
restlessness and xerostomia 8. Kolber et al. (2003)16 empha-
size that incidence of adverse effects was observed in clini-
cal studies sponsored by a pharmaceutical manufacturer, 
in which 35% of patients had not completed treatment.
Table 1. Portuguese version of Fagerström scale for nicotine-dependence evaluation (adapted by Do Carmo; Pueyo, 2002).
Questão Resposta Pontuação
1. Quanto tempo você demora para fumar o primeiro cigarro da manhã? menos de 5 minutos 3
 6-30 minutos 2
 31-60 minutos 1
 mais de 60 minutos 0
2. É difícil abster-se e não fumar nos lugares onde é proibido  sim 1
   (p. ex., hospital, biblioteca, igreja, ônibus, etc.)? não 0
3. Se tivesse de escolher, que cigarro lhe custaria mais deixar de fumar? o primeiro da manhã 1
 todos os demais 0
4. Quantos cigarros você fuma por dia? 10 ou menos 0
 11-20 1
 21-30 2
 31 ou mais 3
5. Habitualmente você fuma mais nas primeiras horas do dia do que  sim 1
  no restante do dia? não 0
6. Você fuma estando doente na cama? sim 1
 não 0
NOTE: score from zero to three: low nicotine-dependency (mild); score higher or equal to seven indicates high nicotine-dependency (severe).
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The authors carried out an independent study to 
evaluate 39 patients, out of which 15 (38%) discontinued 
the use of bupropion due to adverse neuropsychiatric 
effects (trembling, restlessness, and confusion), insomnia 
and skin eruptions. Seven patients (18%) had to reduce 
bupropion dosage to 150 mg/day, so side effects could 
be tolerated.
Risk of convulsions in bupropion users is 1:1.000. 
For this reason, this drug is contraindicated for epileptics4. 
Other contraindications include: nutrient disorders (nerv-
ous anorexia or bulimia), uncontrolled arterial hyperten-
sion, recent alcohol abstinence and use of monoaminoxi-
dase inhibitors (tranylcypromine or selegiline)2,4,8.
Bupropion is a B-category drug according to Food 
and Drug Administration, which means that there are not 
sufficient studies on secure use of this medicine during 
pregnancy4.
Nicotine Replacement Therapy (NRT)
Combined use of NRT and bupropion almost dou-
bles the success rate of smoking cessation14.
In Brazil, nicotine patches and chewing gum are 
available in the market. In the United States, there is also 
the nasal spray and nicotine mouthwash14.
Patches may be found in the Brazilian market in 
dosages of 7, 14 and 21mg/unit and each pack contains 
seven units. They maintain blood levels of nicotine for 16 
to 24 hours17, therefore they should be replaced on a daily 
basis. Their effects are observed in two to three days of 
use18. Mean period for treatment is eight weeks4.
Chewing gums contain 2mg of nicotine/unit and 
are sold in packages of 12 units.
The following dosage is recommended18,19:
a) For patients who smoke ≤25 cigarettes per 
day:
1 gum (2mg) at 1-2 hour intervals in the first 4 weeks 
up to maximum of 20 gums per day18
1 gum (2mg) at 2-4 hour intervals from the 5th to 
8th week
1 gum (2mg) at 4-8 hour intervals from the 9th to 
12th week
b) For patients who smoke >25 cigarettes per 
day:
2 gums (4mg) at 1-2 hour intervals in the first 4 
weeks up to maximum of 20 gums per day18
1 gum (2mg) at 2-4 hour intervals from the 5th to 
8th week
1 gum (2mg) at 4-8 hour intervals from the 9th to 
12th week
Gums should be strongly chewed until numbness of 
the mouth mucosa occurs or a tobacco taste is perceived. 
Then the patient should stop chewing and maintain the 
gum between the cheeks and gingival region until numb-
ness disappears, and restart chewing for 30 minutes to 
throw out the gum. Patient should not ingest any type of 
liquid while chewing the gum19.
The patient must stop smoking as soon as he starts 
NRT. The most common systemic effects in nicotine 
replacement are: nausea, hiccups and headache18,20. 
Main adverse effect of nicotine gums is rash of mouth 
mucosa4.
NRT is contraindicated for individuals younger 
than 18 years and those with severe cardiovascular dis-
eases (acute myocardial infarction occurred within the 
previous two weeks and instable angina)4. Use of NRT 
is possible in nicotine-dependent pregnant women and 
during breastfeeding, should treatment risks and benefits 
be appraised2.
Second-Line Therapy
Clonidine may be used at a 0.1 to 0.75 mg dosage 
per day to relieve nicotine-abstinence syndrome’s symp-
toms. Its main adverse effects are sedation and orthostatic 
hypotension. Sudden discontinuation of clonidine may 
produce hypertensive crisis4.
Nortriptyline inhibits noradrenalin and dopamine 
mechanisms in the CNS, producing antidepressive and 
anxiolytic effects. At short-term, its efficacy in smoking 
cessation seems to be similar to that of bupropion4.
Other therapies
Acupuncture
The Acupuncture Consensus Panel of the United 
States National Institutes of Health (NIH) (1998)21 confirms 
that acupuncture “may be useful as a supportive treatment, 
or acceptable alternative, or part of a comprehensive 
program” in drug-addiction therapy, including nicotine 
dependency. According to Approach Consensus and Treat-
ment of Smokers of the Health Ministry (2001)19, “so far, 
there are not sufficient scientific evidences to corroborate 
the efficacy of acupuncture and of other methods, such 
as aromatherapy and hypnosis. Thus, acupuncture “is not 
recommended as a method of choice for smoking cessa-
tion”, although it may be used “if this is the patient’s option 
and if there are no usage contraindications”.
He et al. (2001)22 followed 46 adults who smoked 
10 or more cigarettes per day and divided them into two 
groups. The study group was submitted to electroacu-
puncture, auriculoacupuncture and auriculoacupressure 
(manual technique, without needles) for three weeks. The 
activated spots corresponded to the lungs, airways and 
mouth. Individuals of the control group were submitted 
to acupuncture with stimulation of spots related to the 
muscle-skeletal system, presumably without influence in 
the organs affected by tobacco. Among the study group 
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patients, 32% abandoned smoking, against 23% of the 
control group. The desire to smoke was reduced in both 
groups, although tobacco taste significantly worsened 
among those submitted to acupuncture. According to the 
authors, acupuncture action mechanisms in smoking treat-
ment remain unknown, although it is possible that tobacco 
taste is reduced by this technique, with consequent fall 
of smoking desire.
So far, there are not sufficient evidences that acu-
puncture is effective in treating nicotine dependency13,23, 
even though several patients feel better during smoking 
abstinence13.
Cognitive-behavioral Therapy and Self-support groups
Marques (2001)4 emphasizes that self-support 
groups and psychotherapy – individual or group – with 
counseling sessions are effective adjuvant factors in treat-
ing nicotine dependency. This is especially significant 
when dependency is followed by other affections, such 
as depression and anxiety.
Counseling helps to identify situations in which 
the tobacco-addicted chases a cigarette due to behavioral 
(after the meals, a cup of coffee, when meeting friends) 
or emotional reasons (anxiety, upsetting). Based on that, 
the tobacco-addicted learns several strategies to break 
the link between these factors and the act of automatic 
smoking14.
Behavioral intervention and counseling is the base 
of treatment against tobacco-use among teenagers2.
The National Cancer Institute (INCA) has a toll-free 
phone number 0800-703-7033, where information on 
smoking cessation methods is provided. In the call center 
menu options, INCA informs the phone numbers of state 
coordination centers for smoking treatment under the 
Central Healthcare System (SUS). Smokers that participate 
in smoking cessation groups have the right to receive 
pharmacotherapy without charge.
Assessment of Response to Treatment
Routinely, the main information for the physician to 
evaluate smoking reduction or cessation is self-reported 
smoking cessation. However, in clinical studies, it is fun-
damental to adopt an objective and secure measurement 
to make sure that the patient has really quit smoking.
The most effective method in clinical research 
studies for smoking cessation is blood, saliva or urine 
cotinine tests22.
Another methodology is measurement of carbon 
monoxide (CO) in exhaled air. In the respiratory tract 
CO synthesis occurs through hemoxygenase enzymes, in 
proportional quantity as to local inflammatory process. 
Tobacco-addicted usually presents high levels of CO in 
exhaled air. Approximately 24 hours after smoking cessa-
tion, CO exhaled levels start to fall, indicating pulmonary 
functional recovery. Exhaled CO concentration of non-
smokers is below 10 ppm (parts per million)24.
Some researchers use portable devices to quantify 
exhaled CO, not only for focused clinical evaluation, but 
also to encourage the patient during smoking cessation 
program enrollment24.
A National Study
Haggsträm et al. (2001)20 assessed 169 smokers 
which voluntarily enrolled in a university smoking ces-
sation service. Most people who searched for assistance 
were women (67%), median age (mean 46 years), high 
educational level and motivated to quit smoking due to 
respiratory disorders (85%). Nicotine dependency was 
moderate in 50% of the cases, mild in 27% and severe in 
22%. Proposed treatment was cognitive-behavioral psy-
chotherapy for mild cases, psychotherapy associated with 
pharmacotherapy (or bupropion 300mg/day or NRT) for 
moderate cases, and psychotherapy associated with phar-
macotherapy (bupropion 300mg/day plus NRT) for severe 
cases. About 30% of smokers abandoned the program in 
the first week. At the end of the study, 124 individuals 
remained in the program; 49% had quit smoking and 13% 
significantly reduced cigarette consumption. Success rate 
in smoking cessation was: 23% in psychotherapy, 50% in 
NRT, 59% in bupropion use and 59% in combined use of 
bupropion and NRT. Only one patient had to interrupt the 
use of bupropion due to adverse effects.
DISCUSSION
Ironically, after five centuries, tobacco has gone 
from a medicinal plant –used even to prevent cancer – to 
one of the worst world public health issues.
Nicotine dependency is currently one of the most 
common chronic diseases in the population24. Differently 
from alcohol and illicit drugs, nicotine does not cause 
acute conditions due to overdose in addicted individuals. 
Also, it does not lead to aggressive behavior or worsens 
the psychomotor performance in car driving and ma-
chine operation. Therefore, nicotine dependency is less 
shocking to society than alcohol dependency and other 
psychoactive drugs. Exceptionally, tobacco addicts are 
seen as inconvenient or dangerous – although, there is 
risk to accidentally burn furniture, clothes, tablecloths or 
mattresses and causing disastrous fire.
On the other hand, an increasing number of people 
show their disgust to tobacco and to passive smoking. In 
public places, where smoking is still not prohibited by law, 
smokers’ segregation is commonly seen. These measures 
protect non-smokers, although they are not effective to 
solve nicotine dependency. 
Governmental campaigns against smoking have 
been intensified in the last decade, especially through 
the media and the warnings printed on cigarette packs. 
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However, around ¼ of the Brazilian population is nicotine-
dependents and is subjected to the morbimortality caused 
by tobacco4.  Presumably, effective anti-tobacco advertis-
ing is useful to make people aware of tobacco negative 
effects on health, although not sufficient to eliminate 
nicotine dependency. 
Most tobacco addicts are aware of cigarettes harms 
and want to quit smoking8. However, overcoming prac-
tical challenges to achieve this goal include: 1) lack of 
medical diagnosis on nicotine dependency; 2) abstinence 
discomfort; 3) insufficient number of smoking cessation 
supportive services and free distribution of medicine by 
the public health system. 
It is difficult to compare scientific studies outcomes 
related to efficacy of smoking cessation. Several factors 
must be considered, such as: patients’ cultural and socio-
economic features, reasons for their enrollment on smok-
ing cessation program (spontaneous attitude or disease, 
such as cancer and COPD), nicotine-dependency grade, 
follow-up period and criteria to assess treatment success 
rate (objective or subjective).
Invasive treatments due to smoking complications, 
for instance, have great influence on smoking cessation. 
Laryngectomized patients due to cancer treatment have 
a two-fold probability of smoking abstinence than those 
treated with radiotherapy only3.
According to the literature, bupropion is effective 
in nicotine-dependency treatment, however there are 
several clinical conditions that contraindicate its use2,4,8. 
Presence of side effects is relatively significant, leading to 
dosage reduction or drug discontinuation in about 38% 
of the cases16.
Nicotine replacement therapy presents good out-
comes when associated with bupropion, although it also 
has limitations, besides not being considered for patients 
with severe cardiovascular diseases4.
Acupuncture is a controversial method for smoking 
cessation23, especially because western Medicine has not 
sufficient knowledge on this technique. Scientific occiden-
tal literature tends to consider it innocuous for smoking 
cessation treatment, although, when practiced by a skilled 
physician, the positive effects of acupuncture cannot be 
denied. Moreover, effectiveness mechanisms of acupunc-
ture remain unknown and require thorough research.
CLOSING REMARKS
Otorhinolaryngologists must be aware of available 
therapeutic modalities for nicotine dependence. Scientific 
knowledge, in addition to sensitivity and keenness will 
allow the physician to choose the most adequate and mo-
tivating way to encourage patients to quit smoking, reduce 
unpleasant symptoms of abstinence and avoid relapses.
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